These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cancer trends in the United States--a view from Europe. Quinn MJ J Natl Cancer Inst; 2003 Sep; 95(17):1258-61. PubMed ID: 12953072 [No Abstract] [Full Text] [Related]
3. Prostate cancer screening. Med Lett Drugs Ther; 2008 Nov; 50(1298):85-6. PubMed ID: 18978703 [No Abstract] [Full Text] [Related]
4. The United States Preventive Services Task Force recommendation against prostate-specific antigen screening--point. Ablin RJ Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):391-4. PubMed ID: 22315362 [No Abstract] [Full Text] [Related]
5. Re: Is a screening interval of every 4 years for prostate cancer acceptable? Braillon A J Natl Cancer Inst; 2008 Feb; 100(3):222-3; author reply 223-4. PubMed ID: 18257153 [No Abstract] [Full Text] [Related]
6. The United States Preventive Services Task Force recommendation against prostate-specific antigen screening--counterpoint. Catalona WJ Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):395-7. PubMed ID: 22315363 [No Abstract] [Full Text] [Related]
7. PSA testing: public policy or private penchant? Albertsen PC JAMA; 2006 Nov; 296(19):2371-3. PubMed ID: 17105802 [No Abstract] [Full Text] [Related]
8. Summaries for patients. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med; 2013 May; 158(10):I-28. PubMed ID: 23567761 [No Abstract] [Full Text] [Related]
9. Counseling patients about prostate cancer screening. Foxhall LE; Von Eschenbach AC Am Fam Physician; 2002 May; 65(9):1752, 1754, 1757. PubMed ID: 12018801 [No Abstract] [Full Text] [Related]
11. Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening. Schröder FH N Engl J Med; 2011 Nov; 365(21):1953-5. PubMed ID: 22029756 [No Abstract] [Full Text] [Related]
12. Prostate-cancer screening--what the U.S. Preventive Services Task Force left out. Brett AS; Ablin RJ N Engl J Med; 2011 Nov; 365(21):1949-51. PubMed ID: 22029759 [No Abstract] [Full Text] [Related]
13. Epidemiology and screening for prostate cancer. Moul JW Am J Manag Care; 1997 Aug; 3(8):1200-5; quiz 1208, 1210. PubMed ID: 10170302 [TBL] [Abstract][Full Text] [Related]
14. The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing. Messing EM; Albertsen P; Andriole GL; Carroll PR; Klein EA Urol Oncol; 2012; 30(1):117-9. PubMed ID: 22243597 [No Abstract] [Full Text] [Related]
15. Divergent Responses to Mammography and Prostate-Specific Antigen Recommendations. Martinez KA; Rothberg MB Am J Prev Med; 2017 Oct; 53(4):533-536. PubMed ID: 28318901 [No Abstract] [Full Text] [Related]
16. Group now advises against routine PSA screening. Mitka M JAMA; 2013 Jun; 309(22):2316. PubMed ID: 23757064 [No Abstract] [Full Text] [Related]
17. States renewing attention to prostate cancer. Rossiter C NCSL Legisbrief; 2012 Sep; 20(36):1-2. PubMed ID: 23072022 [No Abstract] [Full Text] [Related]
18. Indications for PSA testing. Barry MJ; Roberts RG JAMA; 1997 Mar; 277(12):955-6. PubMed ID: 9091657 [No Abstract] [Full Text] [Related]
19. Prostate cancer screening--what's a physician to do? Spann SJ Am Fam Physician; 1997 Oct; 56(6):1563-4, 1567-8. PubMed ID: 9351423 [No Abstract] [Full Text] [Related]
20. [Mass screening for prostate cancer will have to wait. The scientific basis insufficient, more efficient markers necessary]. Damber JE Lakartidningen; 2003 Sep; 100(38):2916-8, 2921. PubMed ID: 14558209 [No Abstract] [Full Text] [Related] [Next] [New Search]